1.
Clin Infect Dis
; 40(2): 303-5, 2005 Jan 15.
Artículo
en Inglés
| MEDLINE
| ID: mdl-15655751
RESUMEN
Tolerability of the combination of zidovudine-lamivudine and lopinavir-ritonavir as postexposure prophylaxis (PEP) for human immunodeficiency virus infection was prospectively assessed. A total of 121 patients were enrolled in the study; 23 patients discontinued PEP prematurely for reasons other than adverse events. Of the other 98 patients, 58 (59%) experienced adverse effects, which led to premature PEP discontinuation in 20 cases (20%).